Smoldering Systemic Mastocytosis
specificSlowly progressive systemic mastocytosis with uncertain prognosis. It is characterized by organomegaly and absence of aggressive disease.
13
Centers
17
Active Trials
—
Cancer Funding
Top Centers for Smoldering Systemic Mastocytosis(13)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | NCI Comprehensive Active Research Program | 69.4 |
| 2 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 69.4 |
| 3 | Boston University Cancer CenterBoston, MA Active Research Program | 69.4 |
| 4 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 69.4 |
| 5 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 46.9 |
| 6 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 46.9 |
| 7 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 46.9 |
| 8 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 46.9 |
| 9 | Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive Active Research Program | 46.9 |
| 10 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 46.9 |
| 11 | Dartmouth Cancer CenterLebanon, NH NCI Comprehensive Active Research Program | 46.9 |
| 12 | University of Illinois Cancer CenterChicago, IL Active Research Program | 46.9 |
| 13 | Cancer Center at IllinoisUrbana, IL Active Research Program | 46.9 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →